Prolia

1 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX I 

 

SUMMARY OF PRODUCT CHARACTERISTICS 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



2 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Prolia 60 mg solution for injection in pre-filled syringe 

 

 

2. QUALITATIVE AND QUANTITATIVE COMPOSITION 

 

Each pre-filled syringe contains 60 mg of denosumab in 1 mL of solution (60 mg/mL). 

 

Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (Chinese 

hamster ovary cells) by recombinant DNA technology. 

 

Excipient with known effect 

 

This medicine contains 47 mg sorbitol in each mL of solution. 

 

For the full list of excipients, see section 6.1. 

 

 

3. PHARMACEUTICAL FORM 

 

Solution for injection (injection). 

 

Clear, colourless to slightly yellow solution. 

 

 

4. CLINICAL PARTICULARS 

 

4.1 Therapeutic indications 

 

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In 

postmenopausal women Prolia significantly reduces the risk of vertebral, non-vertebral and hip 

fractures. 

 

Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk 

of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, Prolia 

significantly reduces the risk of vertebral fractures. 

 

Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at 

increased risk of fracture (see section 5.1). 

 

4.2 Posology and method of administration 

 

Posology 

 

The recommended dose is 60 mg denosumab administered as a single subcutaneous injection once 

every 6 months into the thigh, abdomen or upper arm. 

 

Patients must be adequately supplemented with calcium and vitamin D (see section 4.4). 

 

Patients treated with Prolia should be given the package leaflet and the patient reminder card. 

 

The optimal total duration of antiresorptive treatment for osteoporosis (including both denosumab and 

bisphosphonates) has not been established. The need for continued treatment should be re-evaluated 

periodically based on the benefits and potential risks of denosumab on an individual patient basis, 

particularly after 5 or more years of use (see section 4.4). 



3 

 

 

Elderly (age ≥ 65) 

No dose adjustment is required in elderly patients. 

 

Renal impairment 

No dose adjustment is required in patients with renal impairment (see section 4.4 for 

recommendations relating to monitoring of calcium). 

 

No data is available in patients with long-term systemic glucocorticoid therapy and severe renal 

impairment (GFR < 30 ml/min). 

 

Hepatic impairment 

The safety and efficacy of denosumab have not been studied in patients with hepatic impairment (see 

section 5.2). 

 

Paediatric population 

Prolia is not recommended in paediatric patients (age < 18) as the safety and efficacy of Prolia in 

these patients have not been established. Inhibition of RANK/RANK ligand (RANKL) in animal 

studies has been coupled to inhibition of bone growth and lack of tooth eruption (see section 5.3). 

 

Method of administration 

 

For subcutaneous use. 

 

Administration should be performed by an individual who has been adequately trained in injection 

techniques. 

 

The instructions for use, handling and disposal are given in section 6.6. 

 

4.3 Contraindications 

 

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 

 

Hypocalcaemia (see section 4.4). 

 

4.4 Special warnings and precautions for use 

 

Calcium and vitamin D supplementation 

 

Adequate intake of calcium and vitamin D is important in all patients. 

 

Precautions for use 

 

Hypocalcaemia 

It is important to identify patients at risk for hypocalcaemia. Hypocalcaemia must be corrected by 

adequate intake of calcium and vitamin D before initiating therapy. Clinical monitoring of calcium 

levels is recommended before each dose and, in patients predisposed to hypocalcaemia within 

two weeks after the initial dose. If any patient presents with suspected symptoms of hypocalcaemia 

during treatment (see section 4.8 for symptoms) calcium levels should be measured. Patients should 

be encouraged to report symptoms indicative of hypocalcaemia. 

 

In the post-marketing setting, severe symptomatic hypocalcaemia (including fatal cases) has been 

reported (see section 4.8), with most cases occurring in the first weeks of initiating therapy, but it can 

occur later. 

 

Concomitant glucocorticoid treatment is an additional risk factor for hypocalcaemia. 



4 

 

 

Renal impairment 

Patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis are at 

greater risk of developing hypocalcaemia. The risks of developing hypocalcaemia and accompanying 

parathyroid hormone elevations increase with increasing degree of renal impairment. Adequate intake 

of calcium, vitamin D and regular monitoring of calcium is especially important in these patients, see 

above. 

 

Skin infections 

Patients receiving denosumab may develop skin infections (predominantly cellulitis) leading to 

hospitalisation (see section 4.8). Patients should be advised to seek prompt medical attention if they 

develop signs or symptoms of cellulitis. 

 

Osteonecrosis of the Jaw (ONJ) 

ONJ has been reported rarely in patients receiving Prolia for osteoporosis (see section 4.8). 

 

The start of treatment/new treatment course should be delayed in patients with unhealed open soft 

tissue lesions in the mouth. A dental examination with preventive dentistry and an individual 

benefit-risk assessment is recommended prior to treatment with denosumab in patients with 

concomitant risk factors. 

 

The following risk factors should be considered when evaluating a patient’s risk of developing ONJ: 

• potency of the medicinal product that inhibits bone resorption (higher risk for highly potent 

compounds), route of administration (higher risk for parenteral administration) and cumulative 

dose of bone resorption therapy. 

• cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking. 

• concomitant therapies: corticosteroids, chemotherapy, angiogenesis inhibitors, radiotherapy to 

head and neck. 

• poor oral hygiene, periodontal disease, poorly fitting dentures, history of dental disease, 

invasive dental procedures e.g. tooth extractions. 

 

All patients should be encouraged to maintain good oral hygiene, receive routine dental check-ups, 

and immediately report any oral symptoms such as dental mobility, pain or swelling or non-healing of 

sores or discharge during treatment with denosumab. While on treatment, invasive dental procedures 

should be performed only after careful consideration and be avoided in close proximity to denosumab 

administration. 

 

The management plan of the patients who develop ONJ should be set up in close collaboration 

between the treating physician and a dentist or oral surgeon with expertise in ONJ. Temporary 

interruption of treatment should be considered until the condition resolves and contributing risk 

factors are mitigated where possible. 

 

Osteonecrosis of the external auditory canal 

Osteonecrosis of the external auditory canal has been reported with denosumab. Possible risk factors 

for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk 

factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal 

should be considered in patients receiving denosumab who present with ear symptoms including 

chronic ear infections. 

 

Atypical fractures of the femur 

Atypical femoral fractures have been reported in patients receiving denosumab (see section 4.8). 

Atypical femoral fractures may occur with little or no trauma in the subtrochanteric and diaphyseal 

regions of the femur. Specific radiographic findings characterise these events. Atypical femoral 

fractures have also been reported in patients with certain co-morbid conditions (e.g. vitamin D 

deficiency, rheumatoid arthritis, hypophosphatasia) and with use of certain medicinal products (e.g. 



5 

 

bisphosphonates, glucocorticoids, proton pump inhibitors). These events have also occurred without 

antiresorptive therapy. Similar fractures reported in association with bisphosphonates are often 

bilateral; therefore, the contralateral femur should be examined in denosumab-treated patients who 

have sustained a femoral shaft fracture. Discontinuation of denosumab therapy in patients suspected 

to have an atypical femur fracture should be considered pending evaluation of the patient based on an 

individual benefit-risk assessment. During denosumab treatment, patients should be advised to report 

new or unusual thigh, hip, or groin pain. Patients presenting with such symptoms should be evaluated 

for an incomplete femoral fracture. 

 

Long-term antiresorptive treatment 

Long-term antiresorptive treatment (including both denosumab and bisphosphonates) may contribute 

to an increased risk for adverse outcomes such as osteonecrosis of the jaw and atypical femur 

fractures due to significant suppression of bone remodelling (see section 4.2). 

 

Concomitant treatment with other denosumab-containing medicinal products 

Patients being treated with denosumab should not be treated concomitantly with other 

denosumab-containing medicinal products (for prevention of skeletal related events in adults with 

bone metastases from solid tumours). 

 

Dry natural rubber 

The needle cover of the pre-filled syringe contains dry natural rubber (a derivative of latex), which 

may cause allergic reactions. 

 

Warnings for excipients 

This medicine contains 47 mg sorbitol in each mL of solution. The additive effect of concomitantly 

administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) 

should be taken into account. 

 

This medicinal product contains less than 1 mmol sodium (23 mg) per 60 mg that is to say essentially 

‘sodium-free’. 

 

4.5 Interaction with other medicinal products and other forms of interaction 

 

In an interaction study, denosumab did not affect the pharmacokinetics of midazolam, which is 

metabolised by cytochrome P450 3A4 (CYP3A4). This indicates that denosumab should not alter the 

pharmacokinetics of medicinal products metabolised by CYP3A4. 

 

There are no clinical data on the co-administration of denosumab and hormone replacement therapy 

(oestrogen), however the potential for a pharmacodynamic interaction is considered to be low. 

 

In postmenopausal women with osteoporosis the pharmacokinetics and pharmacodynamics of 

denosumab were not altered by previous alendronate therapy, based on data from a transition study 

(alendronate to denosumab). 

 

4.6 Fertility, pregnancy and lactation 

 

Pregnancy 

 

There are no or limited amount of data from the use of denosumab in pregnant women. Studies in 

animals have shown reproductive toxicity (see section 5.3). 

 

Prolia is not recommended for use in pregnant women and women of child-bearing potential not using 

contraception. Women should be advised not to become pregnant during and for at least 5 months 

after treatment with Prolia. Any effects of Prolia are likely to be greater during the second and third 

trimesters of pregnancy since monoclonal antibodies are transported across the placenta in a linear 

fashion as pregnancy progresses, with the largest amount transferred during the third trimester. 



6 

 

 

Breast-feeding 

 

It is unknown whether denosumab is excreted in human milk. In genetically engineered mice in which 

RANKL has been turned off by gene removal (a “knockout mouse”), studies suggest absence of 

RANKL (the target of denosumab see section 5.1) during pregnancy may interfere with maturation of 

the mammary gland leading to impaired lactation post-partum (see section 5.3). A decision on 

whether to abstain from breast-feeding or to abstain from therapy with Prolia should be made, taking 

into account the benefit of breast-feeding to the newborn/infant and the benefit of Prolia therapy to 

the woman. 

 

Fertility 

 

No data are available on the effect of denosumab on human fertility. Animal studies do not indicate 

direct or indirect harmful effects with respect to fertility (see section 5.3). 

 

4.7 Effects on ability to drive and use machines 

 

Prolia has no or negligible influence on the ability to drive and use machines. 

 

4.8 Undesirable effects 

 

Summary of the safety profile 

 

The most common side effects with denosumab (seen in more than one patient in ten) are 

musculoskeletal pain and pain in the extremity. Uncommon cases of cellulitis, rare cases of 

hypocalcaemia, hypersensitivity, osteonecrosis of the jaw and atypical femoral fractures (see 

sections 4.4 and 4.8 - description of selected adverse reactions) have been observed in patients taking 

denosumab. 

 

Tabulated list of adverse reactions 

 

The data in Table 1 below describe adverse reactions reported from Phase II and III clinical trials in 

patients with osteoporosis and breast or prostate cancer patients receiving hormone ablation; and/or 

spontaneous reporting. 

 

The following convention has been used for the classification of the adverse reactions (see table 1): 

very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), 

rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the 

available data). Within each frequency grouping and system organ class, adverse reactions are 

presented in order of decreasing seriousness. 

 

Table 1. Adverse reactions reported in patients with osteoporosis and breast or prostate cancer 

patients receiving hormone ablation 

 

MedDRA system organ class Frequency category Adverse reactions 

Infections and infestations Common 

Common 

Uncommon 

Uncommon 

Uncommon 

Urinary tract infection 

Upper respiratory tract infection 

Diverticulitis1 

Cellulitis1 

Ear infection 

Immune system disorders Rare 

Rare 

Drug hypersensitivity1 

Anaphylactic reaction1 

Metabolism and nutrition 

disorders 

Rare Hypocalcaemia1 



7 

 

MedDRA system organ class Frequency category Adverse reactions 

Nervous system disorders Common Sciatica 

Gastrointestinal disorders Common 

Common 

Constipation 

Abdominal discomfort 

Skin and subcutaneous tissue 

disorders 

Common 

Common 

Common 

Uncommon 

Rash 

Eczema 

Alopecia 

Lichenoid drug eruptions1 

Musculoskeletal and connective 

tissue disorders 

Very common 

Very common 

Rare 

Rare 

Not Known 

Pain in extremity 

Musculoskeletal pain1 

Osteonecrosis of the jaw1 

Atypical femoral fractures1 

Osteonecrosis of the external auditory 

canal2 

1 See section Description of selected adverse reactions 
2 See section 4.4 

 

In a pooled analysis of data from all phase II and phase III placebo-controlled studies, Influenza-like 

illness was reported with a crude incidence rate of 1.2% for denosumab and 0.7% for placebo. 

Although this imbalance was identified via a pooled analysis, it was not identified via a stratified 

analysis. 

 

Description of selected adverse reactions 

 

Hypocalcaemia 

In two phase III placebo-controlled clinical trials in postmenopausal women with osteoporosis, 

approximately 0.05% (2 out of 4,050) of patients had declines of serum calcium levels (less than 

1.88 mmol/l) following Prolia administration. Declines of serum calcium levels (less than 

1.88 mmol/l) were not reported in either the two phase III placebo-controlled clinical trials in patients 

receiving hormone ablation or the phase III placebo-controlled clinical trial in men with osteoporosis. 

 

In the post-marketing setting, rare cases of severe symptomatic hypocalcaemia have been reported 

predominantly in patients at increased risk of hypocalcaemia receiving denosumab, with most cases 

occurring in the first weeks of initiating therapy. Examples of the clinical manifestations of severe 

symptomatic hypocalcaemia have included QT interval prolongation, tetany, seizures and altered 

mental status (see section 4.4). Symptoms of hypocalcaemia in denosumab clinical studies included 

paraesthesias or muscle stiffness, twitching, spasms and muscle cramps. 

 

Skin infections 

In phase III placebo-controlled clinical trials, the overall incidence of skin infections was similar in 

the placebo and the denosumab groups: in postmenopausal women with osteoporosis (placebo [1.2%, 

50 out of 4,041] versus Prolia [1.5%, 59 out of 4,050]); in men with osteoporosis (placebo [0.8%, 

1 out of 120] versus Prolia [0%, 0 out of 120]); in breast or prostate cancer patients receiving 

hormone ablation (placebo [1.7%, 14 out of 845] versus Prolia [1.4%, 12 out of 860]). Skin infections 

leading to hospitalisation were reported in 0.1% (3 out of 4,041) of postmenopausal women with 

osteoporosis receiving placebo versus 0.4% (16 out of 4,050) of women receiving Prolia. These cases 

were predominantly cellulitis. Skin infections reported as serious adverse reactions were similar in the 

placebo (0.6%, 5 out of 845) and the Prolia (0.6%, 5 out of 860) groups in the breast and prostate 

cancer studies. 

 

Osteonecrosis of the jaw 

ONJ has been reported rarely, in 16 patients, in clinical trials in osteoporosis and in breast or prostate 

cancer patients receiving hormone ablation including a total of 23,148 patients (see section 4.4). 

Thirteen of these ONJ cases occurred in postmenopausal women with osteoporosis during the 

phase III clinical trial extension following treatment with denosumab for up to 10 years. Incidence of 



8 

 

ONJ was 0.04% at 3 years, 0.06% at 5 years and 0.44% at 10 years of denosumab treatment. The risk 

of ONJ increased with duration of exposure to denosumab. 

 

Atypical fractures of the femur 

In the osteoporosis clinical trial program, atypical femoral fractures were reported rarely in patients 

treated with denosumab (see section 4.4). 

 

Diverticulitis 

In a single phase III placebo-controlled clinical trial in patients with prostate cancer receiving ADT an 

imbalance in diverticulitis adverse events was observed (1.2% denosumab, 0% placebo). The 

incidence of diverticulitis was comparable between treatment groups in postmenopausal women or 

men with osteoporosis and in women undergoing aromatase inhibitor therapy for non-metastatic 

breast cancer. 

 

Drug-related hypersensitivity reactions 

In the post-marketing setting, rare events of drug-related hypersensitivity, including rash, urticaria, 

facial swelling, erythema, and anaphylactic reactions have been reported in patients receiving Prolia. 

 

Musculoskeletal pain 

Musculoskeletal pain, including severe cases, has been reported in patients receiving Prolia in the 

post-marketing setting. In clinical trials, musculoskeletal pain was very common in both denosumab 

and placebo groups. Musculoskeletal pain leading to discontinuation of study treatment was 

uncommon. 

 

Lichenoid drug eruptions 

Lichenoid drug eruptions (e.g. lichen planus-like reactions) have been reported in patients in the post-

marketing setting. 

 

Other special populations 

 

Renal impairment 

In clinical studies, patients with severe renal impairment (creatinine clearance < 30 mL/min) or 

receiving dialysis were at greater risk of developing hypocalcaemia in the absence of calcium 

supplementation. Adequate intake of calcium and vitamin D is important in patients with severe renal 

impairment or receiving dialysis (see section 4.4). 

 

Reporting of suspected adverse reactions 

 

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 

allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare 

professionals are asked to report any suspected adverse reactions via the national reporting system 

listed in Appendix V. 

 

4.9 Overdose 

 

There is no experience with overdose in clinical studies. Denosumab has been administered in clinical 

studies using doses up to 180 mg every 4 weeks (cumulative doses up to 1,080 mg over 6 months), 

and no additional adverse reactions were observed. 

 

 

5. PHARMACOLOGICAL PROPERTIES 

 

5.1  Pharmacodynamic properties 

 

Pharmacotherapeutic group: Drugs for treatment of bone diseases – Other drugs affecting bone 

structure and mineralisation, ATC code: M05BX04 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc
http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


9 

 

 

Mechanism of action 

 

Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and 

specificity to RANKL, preventing activation of its receptor, RANK, on the surface of osteoclast 

precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast 

formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone. 

 

Pharmacodynamic effects 

 

Prolia treatment rapidly reduced the rate of bone turnover, reaching a nadir for the bone resorption 

marker serum type 1 C-telopeptides (CTX) (85% reduction) by 3 days, with reductions maintained 

over the dosing interval. At the end of each dosing interval, CTX reductions were partially attenuated 

from maximal reduction of ≥ 87% to approximately ≥ 45% (range 45-80%), reflecting the 

reversibility of Prolia’s effects on bone remodelling once serum levels diminish. These effects were 

sustained with continued treatment. Bone turnover markers generally reached pre-treatment levels 

within 9 months after the last dose. Upon re-initiation, reductions in CTX by denosumab were similar 

to those observed in patients initiating primary denosumab treatment. 

 

Immunogenicity 

 

In clinical studies, neutralising antibodies have not been observed for denosumab. Using a sensitive 

immunoassay < 1% of patients treated with denosumab for up to 5 years tested positive for non 

neutralising binding antibodies with no evidence of altered pharmacokinetics, toxicity, or clinical 

response. 

 

Clinical efficacy and safety in postmenopausal women with osteoporosis 

 

Efficacy and safety of denosumab administered once every 6 months for 3 years were investigated in 

postmenopausal women (7,808 women aged 60-91 years, of which 23.6% had prevalent vertebral 

fractures) with baseline bone mineral density (BMD) T-scores at the lumbar spine or total hip 

between –2.5 and –4.0 and a mean absolute 10-year fracture probability of 18.60% (deciles: 

7.9-32.4%) for major osteoporotic fracture and 7.22% (deciles: 1.4-14.9%) for hip fracture. Women 

with other diseases or on therapies that may affect bone were excluded from this study. Women 

received calcium (at least 1,000 mg) and vitamin D (at least 400 IU) supplementation daily. 

 

Effect on vertebral fractures 

Prolia significantly reduced the risk of new vertebral fractures at 1, 2 and 3 years (p < 0.0001) (see 

table 2). 

 

Table 2. The effect of Prolia on the risk of new vertebral fractures 

 

 Proportion of women with fracture (%) Absolute risk 

reduction (%) 

(95% CI) 

Relative risk 

reduction (%) 

(95% CI) 
Placebo 

n = 3,906 

Prolia 

n = 3,902 

0-1 year 2.2 0.9 1.4 (0.8, 1.9) 61 (42, 74)** 

0-2 years 5.0 1.4 3.5 (2.7, 4.3) 71 (61,79)** 

0-3 years 7.2 2.3 4.8 (3.9, 5.8) 68 (59, 74)* 
*p < 0.0001, **p < 0.0001 – exploratory analysis 

 



10 

 

Effect on hip fractures 

Prolia demonstrated a 40% relative reduction (0.5% absolute risk reduction) in the risk of hip fracture 

over 3 years (p < 0.05). The incidence of hip fracture was 1.2% in the placebo group compared to 

0.7% in the Prolia group at 3 years. 

 

In a post-hoc analysis in women > 75 years, a 62% relative risk reduction was observed with Prolia 

(1.4% absolute risk reduction, p < 0.01). 

 

Effect on all clinical fractures 

Prolia significantly reduced fractures across all fracture types/groups (see table 3). 

 

Table 3. The effect of Prolia on the risk of clinical fractures over 3 years 

 

 Proportion of women with 

fracture (%)+ 

Absolute risk 

reduction (%) 

(95% CI) 

Relative risk 

reduction (%) 

(95% CI) Placebo 

n = 3,906 

Prolia 

n = 3,902 

Any clinical fracture1 10.2 7.2 2.9 (1.6, 4.2) 30 (19, 41)*** 

Clinical vertebral fracture 2.6 0.8 1.8 (1.2, 2.4) 69 (53, 80)*** 

Non-vertebral fracture2 8.0 6.5 1.5 (0.3, 2.7) 20 (5, 33)** 

Major non-vertebral fracture3 6.4 5.2 1.2 (0.1, 2.2) 20 (3, 34)* 

Major osteoporotic fracture4 8.0 5.3 2.7 (1.6, 3.9) 35 (22, 45)*** 
*p ≤ 0.05; **p = 0.0106 (secondary endpoint included in multiplicity adjustment), ***p ≤ 0.0001 
+ Event rates based on Kaplan-Meier estimates at 3 years. 
1 Includes clinical vertebral fractures and non-vertebral fractures. 
2 Excludes those of the vertebrae, skull, facial, mandible, metacarpus, and finger and toe phalanges. 
3 Includes pelvis, distal femur, proximal tibia, ribs, proximal humerus, forearm, and hip. 
4 Includes clinical vertebral, hip, forearm, and humerus fractures, as defined by the WHO. 

 

In women with baseline femoral neck BMD ≤ -2.5, Prolia reduced the risk of non-vertebral fracture 

(35% relative risk reduction, 4.1% absolute risk reduction, p < 0.001, exploratory analysis). 

 

The reduction in the incidence of new vertebral fractures, hip fractures and non-vertebral fractures by 

Prolia over 3 years were consistent regardless of the 10-year baseline fracture risk. 

 

Effect on bone mineral density 

Prolia significantly increased BMD at all clinical sites measured, versus placebo at 1, 2 and 3 years. 

Prolia increased BMD by 9.2% at the lumbar spine, 6.0% at the total hip, 4.8% at the femoral neck, 

7.9% at the hip trochanter, 3.5% at the distal 1/3 radius and 4.1% at the total body over 3 years (all 

p < 0.0001). 
 

In clinical studies examining the effects of discontinuation of Prolia, BMD returned to approximately 

pre-treatment levels and remained above placebo within 18 months of the last dose. These data 

indicate that continued treatment with Prolia is required to maintain the effect of the medicinal 

product. Re-initiation of Prolia resulted in gains in BMD similar to those when Prolia was first 

administered. 

 

Open-label extension study in the treatment of postmenopausal osteoporosis 

A total of 4,550 women (2,343 Prolia & 2,207 placebo) who missed no more than one dose of 

investigational product in the pivotal study described above and completed the month 36 study visit 

agreed to enrol in a 7-year, multinational, multicentre, open-label, single-arm extension study to 

evaluate the long-term safety and efficacy of Prolia. All women in the extension study were to receive 

Prolia 60 mg every 6 months, as well as daily calcium (at least 1 g) and vitamin D (at least 400 IU). A 

total of 2,626 subjects (58% of the women included in the extension study i.e. 34% of the women 

included in the pivotal study) completed the extension study. 

 



11 

 

In patients treated with Prolia for up to 10 years, BMD increased from the pivotal study baseline 

by 21.7% at the lumbar spine, 9.2% at the total hip, 9.0% at the femoral neck, 13.0% at the trochanter 

and 2.8% at the distal 1/3 radius. The mean lumbar spine BMD T-score at the end of the study was -

1.3 in patients treated for 10 years. 

 

Fracture incidence was evaluated as a safety endpoint but efficacy in fracture prevention cannot be 

estimated due to high number of discontinuations and open-label design The cumulative incidence of 

new vertebral and non-vertebral fractures were approximately 6.8% and 13.1% respectively, in 

patients who remained on denosumab treatment for 10 years (n = 1,278). Patients who did not 

complete the study for any reason had higher on-treatment fracture rates. 

 

Thirteen adjudicated cases of osteonecrosis of the jaw (ONJ) and two adjudicated cases of atypical 

fractures of the femur occurred during the extension study. 

 

Clinical efficacy and safety in men with osteoporosis 

 

Efficacy and safety of Prolia once every 6 months for 1 year were investigated in 242 men aged 

31-84 years. Subjects with an eGFR < 30 mL/min/1.73 m2 were excluded from the study. All men 

received calcium (at least 1,000 mg) and vitamin D (at least 800 IU) supplementation daily. 

 

The primary efficacy variable was percent change in lumbar spine BMD, fracture efficacy was not 

evaluated. Prolia significantly increased BMD at all clinical sites measured, relative to placebo at 

12 months: 4.8% at lumbar spine, 2.0% at total hip, 2.2% at femoral neck, 2.3% at hip trochanter, and 

0.9% at distal 1/3 radius (all p < 0.05). Prolia increased lumbar spine BMD from baseline in 94.7% of 

men at 1 year. Significant increases in BMD at lumbar spine, total hip, femoral neck and hip 

trochanter were observed by 6 months (p < 0.0001). 

 

Bone histology in postmenopausal women and men with osteoporosis 

 

Bone histology was evaluated in 62 postmenopausal women with osteoporosis or with low bone mass 

who were either naïve to osteoporosis therapies or had transitioned from previous alendronate therapy 

following 1-3 years treatment with Prolia. Fifty nine women participated in the bone biopsy sub-study 

at month 24 (n = 41) and/or month 84 (n = 22) of the extension study in postmenopausal women with 

osteoporosis. Bone histology was also evaluated in 17 men with osteoporosis following 1 year 

treatment with Prolia. Bone biopsy results showed bone of normal architecture and quality with no 

evidence of mineralisation defects, woven bone or marrow fibrosis. Histomorphometry findings in the 

extension study in postmenopausal women with osteoporosis showed that the antiresorptive effects of 

Prolia, as measured by activation frequency and bone formation rates, were maintained over time. 

 

Clinical efficacy and safety in patients with bone loss associated with androgen deprivation 

 

Efficacy and safety of Prolia once every 6 months for 3 years were investigated in men with 

histologically confirmed non-metastatic prostate cancer receiving ADT (1,468 men aged 48-97 years) 

who were at increased risk of fracture (defined as > 70 years, or < 70 years with a BMD T-score at the 

lumbar spine, total hip, or femoral neck < -1.0 or a history of an osteoporotic fracture.) All men 

received calcium (at least 1,000 mg) and vitamin D (at least 400 IU) supplementation daily. 

 

Prolia significantly increased BMD at all clinical sites measured, relative to treatment with placebo at 

3 years: 7.9% at the lumbar spine, 5.7% at the total hip, 4.9% at the femoral neck, 6.9% at the hip 

trochanter, 6.9% at the distal 1/3 radius and 4.7% at the total body (all p < 0.0001). In a prospectively 

planned exploratory analysis, significant increases in BMD were observed at the lumbar spine, total 

hip, femoral neck and the hip trochanter 1 month after the initial dose. 

 

Prolia demonstrated a significant relative risk reduction of new vertebral fractures: 85% (1.6% 

absolute risk reduction) at 1 year, 69% (2.2% absolute risk reduction) at 2 years and 62% (2.4% 

absolute risk reduction) at 3 years (all p < 0.01). 



12 

 

 

Clinical efficacy and safety in patients with bone loss associated with adjuvant aromatase inhibitor 

therapy 

 

Efficacy and safety of Prolia once every 6 months for 2 years were investigated in women with 

non-metastatic breast cancer (252 women aged 35-84 years) and baseline BMD T-scores between 

-1.0 to -2.5 at the lumbar spine, total hip or femoral neck. All women received calcium (at least 

1,000 mg) and vitamin D (at least 400 IU) supplementation daily. 

 

The primary efficacy variable was percent change in lumbar spine BMD, fracture efficacy was not 

evaluated. Prolia significantly increased BMD at all clinical sites measured, relative to treatment with 

placebo at 2 years: 7.6% at lumbar spine, 4.7% at total hip, 3.6% at femoral neck, 5.9% at hip 

trochanter, 6.1% at distal 1/3 radius and 4.2% at total body (all p < 0.0001). 

 

Treatment of bone loss associated with systemic glucocorticoid therapy 

 

Efficacy and safety of Prolia were investigated in 795 patients (70% women and 30% men) aged 20 to 

94 years treated with ≥ 7.5 mg daily oral prednisone (or equivalent). 

 

Two subpopulations were studied: glucocorticoid-continuing (≥ 7.5 mg daily prednisone or its 

equivalent for ≥ 3 months prior to study enrolment; n = 505) and glucocorticoid-initiating (≥ 7.5 mg 

daily prednisone or its equivalent for < 3 months prior to study enrolment; n = 290). Patients were 

randomised (1:1) to receive either Prolia 60 mg subcutaneously once every 6 months or oral 

risedronate 5 mg once daily (active control) for 2 years. Patients received calcium (at least 1,000 mg) 

and vitamin D (at least 800 IU) supplementation daily. 

 

Effect on Bone Mineral Density (BMD) 

In the glucocorticoid-continuing subpopulation, Prolia demonstrated a greater increase in lumbar 

spine BMD compared to risedronate at 1 year (Prolia 3.6%, risedronate 2.0%; p < 0.001) and 2 years 

(Prolia 4.5%, risedronate 2.2%; p < 0.001). In the glucocorticoid-initiating subpopulation, Prolia 

demonstrated a greater increase in lumbar spine BMD compared to risedronate at 1 year (Prolia 3.1%, 

risedronate 0.8%; p < 0.001) and 2 years (Prolia 4.6%, risedronate 1.5%; p < 0.001) 

 

In addition, Prolia demonstrated a significantly greater mean percent increase in BMD from baseline 

compared to risedronate at the total hip, femoral neck, and hip trochanter. 

 

The study was not powered to show a difference in fractures. At 1 year, the subject incidence of new 

radiological vertebral fracture was 2.7% (denosumab) versus 3.2% (risedronate). The subject 

incidence of non-vertebral fracture was 4.3% (denosumab) versus 2.5% (risedronate). At 2 years, the 

corresponding numbers were 4.1% versus 5.8% for new radiological vertebral fractures and 5.3% 

versus 3.8% for non-vertebral fractures. Most of the fractures occurred in the GC-C subpopulation. 

 

Paediatric population 

 

The European Medicines Agency has waived the obligation to submit the results of studies with 

Prolia in all subsets of the paediatric population in the treatment of bone loss associated with sex 

hormone ablative therapy, and in subsets of the paediatric population below the age of 2 in the 

treatment of osteoporosis. See section 4.2 for information on paediatric use. 

 

5.2 Pharmacokinetic properties 

 

Absorption 

 

Following subcutaneous administration of a 1.0 mg/kg dose, which approximates the approved 60 mg 

dose, exposure based on AUC was 78% as compared to intravenous administration at the same dose 



13 

 

level. For a 60 mg subcutaneous dose, maximum serum denosumab concentrations (Cmax) of 

6 mcg/mL (range 1-17 μg/mL) occurred in 10 days (range 2-28 days). 

 

Biotransformation 

 

Denosumab is composed solely of amino acids and carbohydrates as native immunoglobulin and is 

unlikely to be eliminated via hepatic metabolic mechanisms. Its metabolism and elimination are 

expected to follow the immunoglobulin clearance pathways, resulting in degradation to small peptides 

and individual amino acids. 

 

Elimination 

 

After Cmax, serum levels declined with a half-life of 26 days (range 6-52 days) over a period of 

3 months (range 1.5-4.5 months). Fifty-three percent (53%) of patients had no measurable amounts of 

denosumab detected at 6 months post-dose. 

 

No accumulation or change in denosumab pharmacokinetics with time was observed upon 

subcutaneous multiple-dosing of 60 mg once every 6 months. Denosumab pharmacokinetics were not 

affected by the formation of binding antibodies to denosumab and were similar in men and women. 

Age (28-87 years), race and disease state (low bone mass or osteoporosis; prostate or breast cancer) 

do not appear to significantly affect the pharmacokinetics of denosumab. 

 

A trend was observed between higher body weight and lower exposure based on AUC and Cmax. 

However, the trend is not considered clinically important, since pharmacodynamic effects based on 

bone turnover markers and BMD increases were consistent across a wide range of body weight. 

 

Linearity/non-linearity 

 

In dose ranging studies, denosumab exhibited non-linear, dose-dependent pharmacokinetics, with 

lower clearance at higher doses or concentrations, but approximately dose-proportional increases in 

exposures for doses of 60 mg and greater. 

 

Renal impairment 

 

In a study of 55 patients with varying degrees of renal function, including patients on dialysis, the 

degree of renal impairment had no effect on the pharmacokinetics of denosumab. 

 

Hepatic impairment 

 

No specific study in patients with hepatic impairment was performed. In general, monoclonal 

antibodies are not eliminated via hepatic metabolic mechanisms. The pharmacokinetics of denosumab 

is not expected to be affected by hepatic impairment. 

 

Paediatric population 

 

The pharmacokinetic profile in paediatric populations has not been assessed. 

 

5.3 Preclinical safety data 

 

In single and repeated dose toxicity studies in cynomolgus monkeys, denosumab doses resulting 

in 100 to 150 times greater systemic exposure than the recommended human dose had no impact on 

cardiovascular physiology, male or female fertility, or produced specific target organ toxicity. 

 

Standard tests to investigate the genotoxicity potential of denosumab have not been evaluated, since 

such tests are not relevant for this molecule. However, due to its character it is unlikely that 

denosumab has any potential for genotoxicity. 



14 

 

 

The carcinogenic potential of denosumab has not been evaluated in long-term animal studies. 

 

In preclinical studies conducted in knockout mice lacking RANK or RANKL, impairment of lymph 

node formation was observed in the foetus. An absence of lactation due to inhibition of mammary 

gland maturation (lobulo-alveolar gland development during pregnancy) was also observed in 

knockout mice lacking RANK or RANKL. 

 

In a study of cynomolgus monkeys dosed with denosumab during the period equivalent to the first 

trimester at AUC exposures up to 99-fold higher than the human dose (60 mg every 6 months), there 

was no evidence of maternal or foetal harm. In this study, foetal lymph nodes were not examined. 

 

In another study of cynomolgus monkeys dosed with denosumab throughout pregnancy at AUC 

exposures 119-fold higher than the human dose (60 mg every 6 months), there were increased 

stillbirths and postnatal mortality; abnormal bone growth resulting in reduced bone strength, reduced 

haematopoiesis, and tooth malalignment; absence of peripheral lymph nodes; and decreased neonatal 

growth. A no observed adverse effect level for reproductive effects was not established. Following a 

6 month period after birth, bone related changes showed recovery and there was no effect on tooth 

eruption. However, the effects on lymph nodes and tooth malalignment persisted, and minimal to 

moderate mineralisation in multiple tissues was seen in one animal (relation to treatment uncertain). 

There was no evidence of maternal harm prior to labour; adverse maternal effects occurred 

infrequently during labour. Maternal mammary gland development was normal. 

 

In preclinical bone quality studies in monkeys on long-term denosumab treatment, decreases in bone 

turnover were associated with improvement in bone strength and normal bone histology. Calcium 

levels were transiently decreased and parathyroid hormone levels transiently increased in 

ovariectomised monkeys treated with denosumab. 

 

In male mice genetically engineered to express huRANKL (knock-in mice), which were subjected to a 

transcortical fracture, denosumab delayed the removal of cartilage and remodelling of the fracture 

callus compared to control, but biomechanical strength was not adversely affected. 

 

Knockout mice (see section 4.6) lacking RANK or RANKL exhibited decreased body weight, reduced 

bone growth and lack of tooth eruption. In neonatal rats, inhibition of RANKL (target of denosumab 

therapy) with high doses of a construct of osteoprotegerin bound to Fc (OPG-Fc) was associated with 

inhibition of bone growth and tooth eruption. These changes were partially reversible in this model 

when dosing with RANKL inhibitors was discontinued. Adolescent primates dosed with denosumab 

at 27 and 150 times (10 and 50 mg/kg dose) the clinical exposure had abnormal growth plates. 

Therefore, treatment with denosumab may impair bone growth in children with open growth plates 

and may inhibit eruption of dentition. 

 

 

6. PHARMACEUTICAL PARTICULARS 

 

6.1 List of excipients 

 

Acetic acid, glacial* 

Sodium hydroxide (for pH adjustment)* 

Sorbitol (E420) 

Polysorbate 20 

Water for injections 

* Acetate buffer is formed by mixing acetic acid with sodium hydroxide 

 



15 

 

6.2 Incompatibilities 

 

In the absence of compatibility studies, this medicinal product must not be mixed with other 

medicinal products. 

 

6.3 Shelf life 

 

3 years. 

 

Once removed from the refrigerator, Prolia may be stored at room temperature (up to 25°C) for up to 

30 days in the original container. It must be used within this 30 days period. 

 

6.4 Special precautions for storage 

 

Store in a refrigerator (2°C – 8°C). 

Do not freeze. 

Keep the container in the outer carton in order to protect from light. 

 

6.5 Nature and contents of container 

 

One mL solution in a single use pre-filled syringe made from type I glass with stainless steel 27 gauge 

needle, with or without needle guard. 

 

The needle cover of the pre-filled syringe contains dry natural rubber, which is a derivative of latex 

(see section 4.4). 

 

Pack size of one pre-filled syringe, presented in blistered (pre-filled syringe with or without a needle 

guard) or unblistered packaging (pre-filled syringe without a needle guard only). 

 

Not all pack sizes may be marketed. 

 

6.6 Special precautions for disposal and other handling 

 

• Before administration, the solution should be inspected. Do not inject the solution if it contains 

particles, or is cloudy or discoloured. 

• Do not shake. 

• To avoid discomfort at the site of injection, allow the pre-filled syringe to reach room 

temperature (up to 25°C) before injecting and inject slowly. 

• Inject the entire contents of the pre-filled syringe. 

 

Any unused medicinal product or waste material should be disposed of in accordance with local 

requirements. 

 

 

7. MARKETING AUTHORISATION HOLDER 

 

Amgen Europe B.V. 

Minervum 7061 

4817 ZK Breda 

The Netherlands 

 

 



16 

 

8. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/10/618/001 

EU/1/10/618/002 

EU/1/10/618/003 

 

 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 

 

Date of first authorisation: 26 May 2010 

Date of latest renewal: 15 January 2015 

 

 

10. DATE OF REVISION OF THE TEXT 

 

 

 

Detailed information on this medicinal product is available on the website of the European Medicines 

Agency http://www.ema.europa.eu 

 

http://www.ema.europa.eu/
http://www.ema.europa.eu/


17 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX II 

 

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE 

SUBSTANCE AND MANUFACTURERS RESPONSIBLE 

FOR BATCH RELEASE 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY 

AND USE 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE 

MARKETING AUTHORISATION 

 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO 

THE SAFE AND EFFECTIVE USE OF THE MEDICINAL 

PRODUCT 

 

 



18 

 

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE 

AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 

 

Name and address of the manufacturer of the biological active substance 

 

Amgen Singapore Manufacturing 

1 Tuas View Drive 

Singapore 637026 

 

Name and address of the manufacturers responsible for batch release 

 

Amgen Europe B.V. 

Minervum 7061 

4817 ZK Breda 

The Netherlands 

 

Amgen Technology (Ireland) Unlimited Company 

Pottery Road 

Dun Laoghaire 

Co Dublin 

Ireland 

 

Amgen NV 

Telecomlaan 5-7 

1831 Diegem 

Belgium 

 

The printed package leaflet of the medicinal product must state the name and address of the 

manufacturer responsible for the release of the concerned batch. 

 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 

 

Medicinal product subject to medical prescription. 

 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION 

 

• Periodic safety update reports (PSURs) 
 

The requirements for submission of PSURs for this medicinal product are set out in the list of Union 

reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any 

subsequent updates published on the European medicines web-portal. 

 

 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE 

AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 

 

• Risk management plan (RMP) 

 

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance 

activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the 

marketing authorisation and any agreed subsequent updates of the RMP. 

 



19 

 

An updated RMP should be submitted: 

• At the request of the European Medicines Agency; 

• Whenever the risk management system is modified, especially as the result of new information 

being received that may lead to a significant change to the benefit-risk profile or as the result of 

an important (pharmacovigilance or risk minimisation) milestone being reached. 

 

• Additional risk minimisation measures 
 

The MAH shall ensure that a patient reminder card regarding osteonecrosis of the jaw is implemented. 



20 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX III 

 

LABELLING AND PACKAGE LEAFLET 



21 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

A. LABELLING 

 

 



22 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

PRE-FILLED SYRINGE CARTON 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Prolia 60 mg solution for injection in pre-filled syringe 

denosumab 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

1 mL pre-filled syringe containing 60 mg of denosumab (60 mg/mL). 

 

 

3. LIST OF EXCIPIENTS 

 

Acetic acid, glacial, sodium hydroxide, sorbitol (E420), polysorbate 20, water for injections. 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

Solution for injection 

One pre-filled syringe with automatic needle guard. 

One pre-filled syringe. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Subcutaneous use. 

Important: read the package leaflet before handling pre-filled syringe. 

Do not shake. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 

 

Keep out of the sight and reach of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

 



23 

 

9. SPECIAL STORAGE CONDITIONS 

 

Store in a refrigerator. 

Do not freeze. 

Keep the container in the outer carton in order to protect from light. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Amgen Europe B.V. 

Minervum 7061, 

4817 ZK Breda, 

The Netherlands 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/10/618/001 1 pre-filled syringe (blistered) 

EU/1/10/618/002 1 pre-filled syringe (unblistered) 

EU/1/10/618/003 1 pre-filled syringe with automatic needle guard (blistered) 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Prolia 

 

 

17. UNIQUE IDENTIFIER – 2D BARCODE 

 

2D barcode carrying the unique identifier included. 

 

 

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 

 

PC 

SN 

NN 



24 

 

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS 

 

BLISTERED PRE-FILLED SYRINGE  

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Prolia 60 mg injection 

denosumab 

 

 

2. NAME OF THE MARKETING AUTHORISATION HOLDER 

 

Amgen Europe B.V. 

 

 

3. EXPIRY DATE 

 

EXP 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. OTHER 

 

SC 

 

 



25 

 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 

 

PRE-FILLED SYRINGE LABEL (UNBLISTERED) 

 

 

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 

 

Prolia 60 mg injection 

denosumab 

SC 

 

 

2. METHOD OF ADMINISTRATION 

 

 

3. EXPIRY DATE 

 

EXP 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 

 

1 ml 

 

 

6. OTHER 

 



26 

 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 

 

PRE-FILLED SYRINGE LABEL WITH OR WITHOUT NEEDLE GUARD (BLISTERED) 

 

 

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 

 

Prolia 60 mg 

denosumab 

SC 

 

 

2. METHOD OF ADMINISTRATION 

 

 

3. EXPIRY DATE 

 

EXP 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 

 

1 ml 

 

 

6. OTHER 

 



27 

 

REMINDER STICKERS TEXT (included in pack) 

 

 

Next injection 

 

Prolia 60 mg injection 

denosumab 

 

SC 

 

Every 6 months 

 

Amgen Europe B.V. 

 

<…./…./….> 

 

 



28 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

B. PACKAGE LEAFLET 



29 

 

Package leaflet: Information for the user 

 

Prolia 60 mg solution for injection in pre-filled syringe 

denosumab 

 

Read all of this leaflet carefully before you start using this medicine because it contains 

important information for you. 

- Keep this leaflet. You may need to read it again. 

- If you have any further questions, ask your doctor or pharmacist. 

- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, 

even if their signs of illness are the same as yours. 

- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side 

effects not listed in this leaflet. See section 4. 

- Your doctor will give you a patient reminder card, which contains important safety information 

you need to be aware of before and during your treatment with Prolia. 

 

What is in this leaflet 

1. What Prolia is and what it is used for 

2. What you need to know before you use Prolia 

3. How to use Prolia 

4. Possible side effects 

5. How to store Prolia 

6. Contents of the pack and other information 

 

 

1. What Prolia is and what it is used for 

 

What Prolia is and how it works 

 

Prolia contains denosumab, a protein (monoclonal antibody) that interferes with the action of another 

protein, in order to treat bone loss and osteoporosis. Treatment with Prolia makes bone stronger and 

less likely to break. 

 

Bone is a living tissue and is renewed all the time. Oestrogen helps keep bones healthy. After the 

menopause, oestrogen level drops which may cause bones to become thin and fragile. This can 

eventually lead to a condition called osteoporosis. Osteoporosis can also occur in men due to a 

number of causes including ageing and/or a low level of the male hormone, testosterone. It can also 

occur in patients receiving glucocorticoids. Many patients with osteoporosis have no symptoms, but 

they are still at risk of breaking bones, especially in the spine, hips and wrists. 

 

Surgery or medicines that stop the production of oestrogen or testosterone used to treat patients with 

breast or prostate cancer can also lead to bone loss. The bones become weaker and break more easily. 

 

What Prolia is used for 

 

Prolia is used to treat: 

• osteoporosis in women after the menopause (postmenopausal) and men who have an increased 

risk of fracture (broken bones), reducing the risk of spinal, non-spinal and hip fractures. 

• bone loss that results from a reduction in hormone (testosterone) level caused by surgery or 

treatment with medicines in patients with prostate cancer. 

• bone loss that results from long-term treatment with glucocorticoids in patients who have an 

increased risk of fracture. 

 

 



30 

 

2. What you need to know before you use Prolia 

 

Do not use Prolia 

 

• if you have low calcium levels in the blood (hypocalcaemia). 

• if you are allergic to denosumab or any of the other ingredients of this medicine (listed in 

section 6). 

 

Warnings and precautions 

 

Talk to your doctor or pharmacist before using Prolia 

 

Whilst being treated with Prolia you may develop a skin infection with symptoms such as a swollen, 

red area of skin, most commonly in the lower leg, that feels hot and tender (cellulitis), and possibly 

with symptoms of fever. Please tell your doctor immediately if you develop any of these symptoms. 

 

Please tell your doctor if you have an allergy to latex (the needle cover on the pre-filled syringe 

contains a derivative of latex). 

 

You should also take calcium and vitamin D supplements while being on treatment with Prolia. Your 

doctor will discuss this with you. 

 

You may have low levels of calcium in your blood while receiving Prolia. Please tell your doctor 

immediately if you notice any of the following symptoms: spasms, twitches, or cramps in your 

muscle, and/or numbness or tingling in your fingers, toes or around your mouth, and/or seizures, 

confusion, or loss of consciousness. 

 

Tell your doctor if you have or have ever had severe kidney problems, kidney failure or have needed 

dialysis or are taking medicines called glucocorticoids (such as prednisolone or dexamethasone), 

which may increase your risk of getting low blood calcium if you do not take calcium supplements. 

 

Problems with your mouth, teeth or jaw 

A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported rarely 

(may affect up to 1 in 1,000 people) in patients receiving Prolia for osteoporosis. The risk of ONJ 

increases in patients treated for a long time (may affect up to 1 in 200 people if treated for 10 years). 

ONJ can also occur after stopping treatment. It is important to try to prevent ONJ developing as it 

may be a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, 

take the following precautions: 

 

Before receiving treatment, tell your doctor or nurse (health care professional) if you: 

 

• have any problems with your mouth or teeth such as poor dental health, gum disease, or a 

planned tooth extraction. 

• don’t receive routine dental care or have not had a dental check-up for a long time. 

• are a smoker (as this may increase the risk of dental problems). 

• have previously been treated with a bisphosphonate (used to treat or prevent bone disorders). 

• are taking medicines called corticosteroids (such as prednisolone or dexamethasone). 

• have cancer. 

 

Your doctor may ask you to undergo a dental examination before you start treatment with Prolia. 

 

While being treated, you should maintain good oral hygiene and receive routine dental check-ups. If 

you wear dentures you should make sure these fit properly. If you are under dental treatment or will 

undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and 

tell your dentist that you are being treated with Prolia. 



31 

 

 

Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth 

such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of 

ONJ. 

 

Unusual thigh bone fractures 

Some people have developed unusual fractures in their thigh bone while being treated with Prolia. 

Contact your doctor if you experience new or unusual pain in your hip, groin, or thigh. 

 

Children and adolescents 

 

Prolia is not recommended for children and adolescents under 18 years of age. The use of Prolia in 

children and adolescents has not been studied. 

 

Other medicines and Prolia 

 

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 

medicines. It is especially important that you tell your doctor if you are being treated with another 

medicine containing denosumab. 

 

You should not take Prolia together with another medicine containing denosumab. 

 

Pregnancy and breast-feeding 

 

Prolia has not been tested in pregnant women. It is important to tell your doctor if you are pregnant; 

think you may be pregnant; or plan to get pregnant. Prolia is not recommended for use if you are 

pregnant. Women of child-bearing potential should use effective methods of contraception while 

being treated with Prolia and for at least 5 months after stopping treatment with Prolia. 

 

If you become pregnant during treatment with Prolia or less than 5 months after stopping treatment 

with Prolia, please inform your doctor. 

 

It is not known whether Prolia is excreted in breast milk. It is important to tell your doctor if you are 

breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding, 

or whether to stop taking Prolia, considering the benefit of breast-feeding to the baby and the benefit 

of Prolia to the mother. 

 

If you are breast-feeding during Prolia treatment, please inform your doctor. 

 

Ask your doctor or pharmacist for advice before taking any medicine. 

 

Driving and using machines 

 

Prolia has no or negligible influence on the ability to drive and use machines. 

 

Prolia contains sorbitol 

 

This medicine contains 47 mg sorbitol in each mL of solution. 

 

Prolia contains sodium 

 

This medicine contains less than 1 mmol sodium (23 mg) per 60 mg, that is to say essentially 

‘sodium-free’. 

 

 



32 

 

3. How to use Prolia 

 

The recommended dose is one pre-filled syringe of 60 mg administered once 

every 6 months, as a single injection under the skin (subcutaneous). The best 

places to inject are the top of your thighs and the abdomen. Your carer can 

also use the outer area of your upper arm. Each pack of Prolia contains a 

reminder card with stickers that can be removed from the carton. Use the 

peel-off stickers to mark the next injection date on your personal calendar 

and/or the reminder card to keep a record of the next injection date. 

 

 

You should also take calcium and vitamin D supplements while being on treatment with Prolia. Your 

doctor will discuss this with you. 

 

Your doctor may decide that it is best for you or a carer to inject Prolia. Your doctor or healthcare 

provider will show you or your carer how to use Prolia. For instructions on how to inject Prolia, 

please read the section at the end of this leaflet. 

 

Do not shake. 

 

If you forget to use Prolia 

 

If a dose of Prolia is missed, the injection should be administered as soon as possible. Thereafter, 

injections should be scheduled every 6 months from the date of the last injection. 

 

If you stop using Prolia 

 

To get the most benefit from your treatment, it is important to use Prolia for as long as your doctor 

prescribes it for you. Please talk to your doctor before you consider stopping the treatment. 

 

 

4. Possible side effects 

 

Like all medicines, this medicine can cause side effects, although not everybody gets them. 

 

Uncommonly, patients receiving Prolia may develop skin infections (predominantly cellulitis). Please 

tell your doctor immediately if you develop any of these symptoms while being on treatment with 

Prolia: swollen, red area of skin, most commonly in the lower leg, that feels hot and tender, and 

possibly with symptoms of fever. 

 

Rarely, patients receiving Prolia may develop pain in the mouth and/or jaw, swelling or non-healing 

of sores in the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of 

a tooth. These could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and 

dentist immediately if you experience such symptoms while being treated with Prolia or after 

stopping treatment. 

 

Rarely, patients receiving Prolia may have low calcium levels in the blood (hypocalcaemia). 

Symptoms include spasms, twitches, or cramps in your muscles, and/or numbness or tingling in your 

fingers, toes or around your mouth and/or seizures, confusion, or loss of consciousness. If any of these 

apply to you, tell your doctor immediately. Low calcium in the blood may also lead to a change in 

heart rhythm called QT prolongation which is seen by electrocardiogram (ECG). 

 

Rarely unusual fractures of the thigh bone may occur in patients receiving Prolia. Contact your 

doctor if you experience new or unusual pain in your hip, groin or thigh as this may be an early 

indication of a possible fracture of the thigh bone. 



33 

 

 

Rarely, allergic reactions may occur in patients receiving Prolia. Symptoms include swelling of the 

face, lips, tongue, throat or other parts of the body; rash, itching or hives on the skin, wheezing or 

difficulty breathing. Please tell your doctor if you develop any of these symptoms while being 

treated with Prolia. 

 

Very common side effects (may affect more than 1 in 10 people): 

 

• bone, joint, and/or muscle pain which is sometimes severe, 

• arm or leg pain (pain in extremity). 

 

Common side effects (may affect up to 1 in 10 people): 

 

• painful urination, frequent urination, blood in the urine, inability to hold your urine, 

• upper respiratory tract infection, 

• pain, tingling or numbness that moves down your leg (sciatica), 

• constipation, 

• abdominal discomfort, 

• rash, 

• skin condition with itching, redness and/or dryness (eczema), 

• hair loss (alopecia). 

 

Uncommon side effects (may affect up to 1 in 100 people): 

 

• fever, vomiting and abdominal pain or discomfort (diverticulitis), 

• ear infection, 

• rash that may occur on the skin or sores in the mouth (lichenoid drug eruptions). 

 

Not known (frequency cannot be estimated from the available data): 

 

• Talk to your doctor if you have ear pain, discharge from the ear and/or an ear infection. These 

could be signs of bone damage in the ear. 

 

Reporting of side effects 

 

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 

not listed in this leaflet. You can also report side effects directly via the national reporting system 

listed in Appendix V. By reporting side effects you can help provide more information on the safety 

of this medicine. 

 

 

5. How to store Prolia 

 

Keep this medicine out of the sight and reach of children. 

 

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The 

expiry date refers to the last day of that month. 

 

Store in a refrigerator (2°C – 8°C). 

Do not freeze. 

Keep the container in the outer carton in order to protect from light. 

 

Your pre-filled syringe may be left outside the refrigerator to reach room temperature (up to 25°C) 

before injection. This will make the injection more comfortable. Once your syringe has been left to 

reach room temperature (up to 25°C), it must be used within 30 days. 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc
http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


34 

 

 

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 

throw away medicines you no longer use. These measures will help to protect the environment. 

 

 

6. Contents of the pack and other information 

 

What Prolia contains 

 

- The active substance is denosumab. Each 1 mL pre-filled syringe contains 60 mg of denosumab 

(60 mg/mL). 

- The other ingredients are acetic acid, glacial, sodium hydroxide, sorbitol (E420), 

polysorbate 20 and water for injections. 

 

What Prolia looks like and contents of the pack 

 

Prolia is a clear, colourless to slightly yellow solution for injection provided in a ready to use 

pre-filled syringe. 

 

Each pack contains one pre-filled syringe with a needle guard. 

Each pack contains one pre-filled syringe. 

 

Not all pack sizes may be marketed. 

 

Marketing Authorisation Holder and Manufacturer 

Amgen Europe B.V. 

Minervum 7061, 

4817 ZK Breda, 

The Netherlands 

 

Marketing Authorisation Holder 

Amgen Europe B.V. 

Minervum 7061 

4817 ZK Breda 

The Netherlands 

 

Manufacturer 

Amgen Technology (Ireland) Unlimited Company 

Pottery Road 

Dun Laoghaire 

Co Dublin 

Ireland 

 

Manufacturer 

Amgen NV 

Telecomlaan 5-7 

1831 Diegem 

Belgium 

 



35 

 

For any information about this medicine, please contact the local representative of the Marketing 

Authorisation Holder. 

 

België/Belgique/Belgien 

s.a. Amgen n.v. 

Tel/Tél: +32 (0)2 7752711 

 

Lietuva 

Amgen Switzerland AG Vilniaus filialas 

Tel: +370 5 219 7474 

България 

Амджен България ЕООД 

Тел.: +359 (0)2 424 7440 

Luxembourg/Luxemburg 

s.a. Amgen 

Belgique/Belgien 

Tel/Tél: +32 (0)2 7752711 

 

Česká republika 

Amgen s.r.o. 

Tel: +420 221 773 500 

Magyarország 

Amgen Kft. 

Tel.: +36 1 35 44 700 

Danmark 

Amgen, filial af Amgen AB, Sverige 

Tlf: +45 39617500 

 

Malta 

Amgen B.V. 

The Netherlands 

Tel: +31 (0)76 5732500 

 

Deutschland 

AMGEN GmbH 

Tel.: +49 89 1490960 

 

Nederland 

Amgen B.V. 

Tel: +31 (0)76 5732500 

 

Eesti 

Amgen Switzerland AG Vilniaus filialas 

Tel: +372 586 09553 

Norge 

Amgen AB 

Tlf: +47 23308000 

 

Ελλάδα 

Amgen Ελλάς Φαρμακευτικά Ε.Π.Ε. 

Τηλ.: +30 210 3447000 

 

Österreich 

Amgen GmbH 

Tel: +43 (0)1 50 217 

 

España 

Amgen S.A.  

Tel: +34 93 600 18 60 

 

Polska 

Amgen Biotechnologia Sp. z o.o. 

Tel.: +48 22 581 3000 

France 

Amgen S.A.S. 

Tél: +33 (0)9 69 363 363  

Portugal 

Amgen Biofarmacêutica, Lda. 

Tel: +351 21 4220606 

 

Hrvatska 

Amgen d.o.o. 

Tel: +385 (0)1 562 57 20 

România 

Amgen România SRL 

Tel: +4021 527 3000 

 

Ireland 

Amgen Ireland Limited 

Tel: +353 1 8527400 

 

Slovenija 

AMGEN zdravila d.o.o. 

Tel: +386 (0)1 585 1767 

Ísland 

Vistor hf. 

Sími: +354 535 7000 

 

Slovenská republika 

Amgen Slovakia s.r.o. 

Tel: +421 2 321 114 49 

 



36 

 

Italia 

Amgen S.r.l. 

Tel: +39 02 6241121 

Suomi/Finland 

Amgen AB, sivuliike Suomessa/Amgen AB, filial 

i Finland 

Puh/Tel: +358 (0)9 54900500 

 

Kύπρος 

C.A. Papaellinas Ltd 

Τηλ: +357 22741 741 

Sverige 

Amgen AB 

Tel: +46 (0)8 6951100 

 

Latvija 

Amgen Switzerland AG Rīgas filiāle 

Tel: +371 257 25888 

United Kingdom 

Amgen Limited 

Tel: +44 (0)1223 420305 

 

This leaflet was last revised in 

 

Other sources of information 

 

Detailed information on this medicine is available on the European Medicines Agency web site: 

http://www.ema.europa.eu/ 

 

--------------------------------------------------------------------------------------------------------------------------- 

http://www.ema.europa.eu/
http://www.ema.europa.eu/


37 

 

 

Instructions for use: 

 

Guide to parts 

Before use After use 
 

Plunger 

Finger grips 

Syringe label 

Syringe barrel 

Syringe safety guard 

Needle safety spring 

Grey needle cap on 
 

 
 

 

Used plunger 

Syringe label 

Used syringe barrel 

Used needle 

Used needle safety 

spring 

Grey needle cap off 

 

 



38 

 

Important 

Before you use a Prolia pre-filled syringe with automatic needle guard, read this important 

information: 

•  It is important that you do not try to give yourself the injection unless you have received 

training from your doctor or healthcare provider. 

•  Prolia is given as an injection into the tissue just under the skin (subcutaneous injection). 

•  Tell your doctor if you have an allergy to latex (the needle cap on the pre-filled syringe 

contains a derivative of latex). 

 Do not remove the grey needle cap from the pre-filled syringe until you are ready to inject. 

 Do not use the pre-filled syringe if it has been dropped on a hard surface. Use a new pre-filled 

syringe and call your doctor or healthcare provider. 

 Do not attempt to activate the pre-filled syringe prior to injection. 

 Do not attempt to remove the clear pre-filled syringe safety guard from the pre-filled syringe. 

Call your doctor or healthcare provider if you have any questions. 

 

Step 1: Prepare 

A Remove the pre-filled syringe tray from the package and gather the supplies needed for your 

injection: alcohol wipes, a cotton ball or gauze pad, a plaster and a sharps disposal container 

(not included). 

For a more comfortable injection, leave the pre-filled syringe at room temperature for about 

30 minutes before injecting. Wash your hands thoroughly with soap and water. 

 

On a clean, well-lit work surface, place the new pre-filled syringe and the other supplies. 

 Do not try to warm the syringe by using a heat source such as hot water or microwave. 

 Do not leave the pre-filled syringe exposed to direct sunlight. 

 Do not shake the pre-filled syringe. 

•  Keep the pre-filled syringe out of the sight and reach of children. 

 

B Open the tray, peeling away the cover. Grab the pre-filled syringe safety guard to remove the 

pre-filled syringe from the tray. 

 

Grab here 

For safety reasons: 

 Do not grasp the plunger. 

 Do not grasp the grey needle cap. 

 



39 

 

C Inspect the medicine and pre-filled syringe. 

 Medicine 

 

 Do not use the pre-filled syringe if: 

• The medicine is cloudy or there are particles in it. It must be a clear, colourless to slightly 

yellow solution. 

• Any part appears cracked or broken. 

• The grey needle cap is missing or not securely attached. 

• The expiry date printed on the label has passed the last day of the month shown. 

In all cases, call your doctor or healthcare provider. 

 

Step 2: Get ready 

A Wash your hands thoroughly. Prepare and clean your injection site. 

You can use: 

 

Upper arm 

 
 

Belly 

Upper thigh 

• Upper part of your thigh. 

• Belly, except for a 5 cm (2-inch) area right around your belly button. 

• Outer area of upper arm (only if someone else is giving you the injection). 

Clean the injection site with an alcohol wipe. Let your skin dry. 

 Do not touch the injection site before injecting. 

 Do not
 inject into areas where the skin is tender, bruised, red, or hard. Avoid injecting into 

areas with scars or stretch marks. 

 



40 

 

B Carefully pull the grey needle cap straight out and away from your body. 

 

 

C Pinch your injection site to create a firm surface. 

 

 It is important to keep the skin pinched when injecting. 

 

Step 3: Inject 

A Hold the pinch. INSERT the needle into skin. 

 

 Do not touch the cleaned area of the skin. 

 



41 

 

B PUSH the plunger with slow and constant pressure until you feel or hear a “snap”. Push all 

the way down through the snap. 

 

 
“SNAP” 

 

 

 

 It is important to push down through the “snap” to deliver your full dose. 

 

C RELEASE your thumb. Then LIFT the syringe off skin. 

 

After releasing the plunger, the pre-filled syringe safety guard will safely cover the injection needle. 

 Do not put the grey needle cap back on used pre-filled syringes. 

 



42 

 

Step 4: Finish 

A Discard the used pre-filled syringe and other supplies in a sharps disposal container. 

 

Medicines should be disposed of in accordance with local requirements. Ask your pharmacist how to 

dispose of medicines no longer required. These measures will help to protect the environment. 

 

Keep the syringe and sharps disposal container out of sight and reach of children. 

 Do not reuse the pre-filled syringe. 

 Do not recycle pre-filled syringes or throw them into household waste. 

 

B Examine the injection site. 

If there is blood, press a cotton ball or gauze pad on your injection site. Do not rub the injection site. 

Apply a plaster if needed. 

 

 



43 

 

 

Instructions for injecting with the Prolia pre-filled syringe 

 

This section contains information on how to use the Prolia pre-filled syringe. It is important that 

you or your carer do not give the injection unless training from your doctor or healthcare 

provider has been received. Always wash your hands before every injection. If you have questions 

about how to inject, please ask your doctor or healthcare provider for assistance. 

 

Before you begin 

 

Read all instructions thoroughly before using the pre-filled syringe. 

 

DO NOT use the pre-filled syringe if the needle cover has been removed. 

 

How do you use the Prolia pre-filled syringe? 

 

Your doctor has prescribed a Prolia pre-filled syringe for injection into the tissue just under the skin 

(subcutaneous). You must inject the entire content (1 mL) of the Prolia pre-filled syringe and it should 

be injected once every 6 months as instructed by your doctor. 

 

Equipment: 

 

To give an injection, you will need: 

 

1. A new Prolia pre-filled syringe 

 

2. Alcohol wipes or similar. 

 

What to do before you give a subcutaneous injection of Prolia 

 

1. Remove the pre-filled syringe from the refrigerator. 

DO NOT pick up the pre-filled syringe by the plunger or needle cover. This could damage the 

device. 

 

2. The pre-filled syringe may be left outside the refrigerator to reach room temperature. This will 

make the injection more comfortable. 

DO NOT warm it in any other way, for example, in a microwave or in hot water. 

DO NOT leave the syringe exposed to direct sunlight. 

 

3. DO NOT shake the pre-filled syringe. 

 

4. DO NOT remove the needle cover from the pre-filled syringe until you are ready to inject. 

 

5. Check the expiry date on the pre-filled syringe label (EXP). 

DO NOT use it if the date has passed the last day of the month shown. 

 

6. Check the appearance of Prolia. It must be a clear, colourless to slightly yellow solution. The 

solution should not be injected if it contains particles or if it is discoloured or cloudy. 

 

7. Find a comfortable, well-lit, clean surface and put all the equipment within reach. 

 

8. Wash your hands thoroughly. 

 

 



44 

 

Where should you give the injection? 

The best places to inject are the top of your thighs and the 

abdomen. 

Your carer can also use the outer area of your upper arms. 

 

 

How do you give the injection? 

 

1. Disinfect the skin by using an alcohol wipe. 

 

2. To avoid bending the needle, gently pull the cover 

from the needle straight off without twisting, as 

shown in pictures 1 and 2. 

DO NOT touch the needle or push the plunger. 

 

3. You may notice a small air bubble in the pre-filled 

syringe. You do not have to remove the air bubble 

before injecting. Injecting the solution with the air 

bubble is harmless. 

 

4. Pinch (without squeezing) the skin between your 

thumb and forefinger. Put the needle fully into the 

skin as shown by your doctor or healthcare provider. 

 

5. Push the plunger with a slow constant pressure, always keeping the skin pinched. Push the 

plunger all the way down as far as it will go to inject all the solution. 

 

6. Remove the needle and let go of the skin. 

 

7. If you notice a spot of blood you may gently dab it away with a cotton ball or tissue. Do not rub 

the injection site. If needed, you may cover the injection site with a plaster. 

 

8. Only use each pre-filled syringe for one injection. DO NOT use any Prolia that is left in the 

syringe. 

 

Remember: if you have any problems, please ask your doctor or healthcare provider for help and 

advice. 

 

Disposing of used syringes 

 

• DO NOT put the cover back on used needles. 

• Keep used syringes out of the reach and sight of children. 

• The used syringe should be disposed of in accordance with local requirements. Ask your 

pharmacist how to dispose of medicines no longer required. These measures will help to protect 

the environment. 
 


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET